Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Sylentis, Alnylam, UMass Medical, and More

Premium

Title: siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2

Patent Number: 8,247,169

Filed: March 1, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2.”


Titles: Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure

Patent Numbers: 8,247,386 & 8,247,387

Filed: July 9, 2008

Lead Inventor: Ana Jimenez, Sylentis

The patents, their abstracts state, claim “methods and compositions that decrease intraocular pressure of the eye. The compositions of the invention comprise short interfering nucleic acid molecules ... that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of eye conditions displaying increased [intraocular pressure] such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.”


Title: Role of miRNA in T Cell Leukemia

Patent Number: 8,247,388

Filed: June 8, 2009

Lead Inventor: Chang-Zheng Chen, Stanford University

“The ability of miR-181a to support active signaling between Notch and pre-TCR pathways by coordinately dampening negative regulators of these pathways allows the use of miR-181a as a therapeutic target for T-ALL,” the patent's abstract states.


Title: Human microRNAs and Methods of Inhibiting Same

Patent Number: 8,247,543

Filed: May 1, 2006

Lead Inventor: Thomas Tuschl, Rockefeller University

“The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a [predefined] microRNA … except that up to thirty percent of the bases may be wobble bases, and up to 10 [percent] of the contiguous bases may be non-complementary,” according to the patent's abstract. “The invention further relates to modified single stranded microRNA molecules, isolated single stranded anti-microRNA molecules and isolated microRNP molecules. In another embodiment, the invention relates to a method for inhibiting microRNP activity in a cell.”


Title: Small Interfering RNAs and Methods for Prevention, Inhibition, and/or Treatment of Malignant Progression of Breast Cancer

Application Number: 20120207817

Filed: Feb. 14, 2011

Lead Inventor: Chia-Hwa Lee, Taipei Medical University

“Over-expression and activation of alpha-9-nAChR are associated with tumorigenesis of breast cancer,” the patent application's abstract states. Inhibition of breast cancer using siRNAs to inhibit the expression of alpha-9-nAChR is also possible. “Therefore, the invention provides small interfering RNAs for inhibiting expression of alpha-9-nAChR so as to inhibit breast cancer, methods to prevent/inhibit/treat malignant progression of nicotine-derived-compound-induced breast cancer, and method of determining malignant level of such breast cancer.”


Title: System for Synergistic Expression of Multiple Small Functional RNA Elements

Application Number: 20120208267

Filed: Nov. 14, 2011

Lead Inventor: Jeffrey Friedman, University of Southern California

The invention, the patent application's abstract states, “relates in general to microRNAs. More specifically, the invention relates to expression vectors comprising multiple miRNAs or families and clusters capable of targeting multiple oncogenic pathways.”


Title: Compositions and Methods for Inhibiting Expression of Factor VII Gene

Application Number: 20120208860

Filed: Dec. 16, 2010

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the factor VII gene,” the patent application's abstract states.


Title: RIP140 Regulation of Glucose Transport

Application Number: 20120208862

Filed: Jan. 6, 2012

Lead Inventor: Michael Czech, University of Massachusetts Medical School

“Inhibition of RIP140 increases glucose transport,” according to the patent application's abstract. “Compounds that inhibit RIP140 expression or activity, [namely siRNAs], are useful for treating disorders associated with aberrant glucose transport, treating obesity, increasing metabolism, and increasing brown fat.”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.